| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. | Neuropsychopharmacology | 2005 | 3.78 |
| 2 | Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant. | Biol Psychiatry | 2004 | 1.28 |
| 3 | Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression. | Neuropsychopharmacology | 2004 | 1.10 |
| 4 | Is bigger better for depression trials? | J Psychiatr Res | 2007 | 0.92 |
| 5 | Montelukast for migraine prophylaxis: a randomized, double-blind, placebo-controlled study. | Headache | 2004 | 0.88 |
| 6 | Addition of an NK1 receptor antagonist to an SSRI did not enhance the antidepressant effects of SSRI monotherapy: results from a randomized clinical trial in patients with major depressive disorder. | Hum Psychopharmacol | 2014 | 0.76 |
| 7 | Look-alike, sound-alike drug errors with Reminyl and Amaryl. | Am J Health Syst Pharm | 2005 | 0.75 |